Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMXIN002 intranasal epinephrine versus intramuscular epinephrine for food-challenge-induced anaphylaxis
MOH_2025-05-14_014095Phase 2Recruiting
- Sponsor
- Nasus Pharma
- Start
- Apr 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FMXIN002 and epinephrine in anaphylaxis (2 arms), sponsored by Nasus Pharma. Primary endpoint: Clinical resolution of anaphylactic reaction. Started Apr 2025; status: recruiting.
02
Drugs
FMXIN002epinephrine
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on MOH_2025-05-14_014095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-14_014095.